Investors should focus on the mid-2026 data readout for MICVO monotherapy with modified dosing, which could validate improved safety and sustained efficacy. The cash runway into Q4 2026 suggests potential need for financing if development accelerates.
Price Chart
Executive Summary
Pyxis Oncology reported financial results for 2025 and provided a clinical update on its lead asset, micvotabart pelidotin (MICVO), in head and neck cancer. The company completed enrollment in its Phase 1 monotherapy dose expansion study and expects updated data mid-2026. Preliminary data showed strong response rates, but revenues declined year-over-year due to lower milestone and royalty income. The company has sufficient cash to fund operations into Q4 2026.
Key Financial Metrics
Key Facts
- Completed target enrollment in Phase 1 monotherapy dose expansion study of MICVO in 2L+ R/M HNSCC in Q1 2026
- Preliminary monotherapy data: 46% ORR and 92% DCR in 13 efficacy-evaluable patients
- Combination with KEYTRUDA®: 71% ORR and 100% DCR in 7 patients
- Revenues decreased to $13.9M in 2025 from $16.1M in 2024
- R&D expenses increased to $73.7M from $58.7M in 2024
- Net loss widened to $79.6M in 2025 from $77.3M in 2024
- Cash and short-term investments totaled $68.3M as of Dec 31, 2025, funding operations into Q4 2026
- Appointed Thomas Civik as Interim CEO in February 2026
Financial Impact
Revenue declined by 13.7% YoY to $13.9M, while R&D spending increased by $15M. Net loss widened slightly despite lower G&A costs.
Risk Factors
- Clinical data is based on small patient numbers (n=13 monotherapy, n=7 combination)
- Revenue decline reflects reliance on non-recurring milestone and royalty sales
- Increased R&D spend without near-term commercial revenue increases financial risk
- Dosing modifications may not improve safety in larger cohorts
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260234 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 8-K | $3.38 $3.34 | ▼ −1.18% | ▼ −0.09% | $2.19 (−35.21%) |
Sep 8, 2026 24d ago | 8-K | $3.89 $3.33 | ▼ −14.40% | ▼ −13.28% | $2.19 (−43.70%) |
Aug 28, 2026 5w ago | EFFECT | $3.23 $3.89 | ▼ −20.43% | ▼ −20.32% | $2.19 (+32.20%) |
Aug 13, 2026 7w ago | 8-K | $3.01 $3.12 | ▲ +3.65% | ▲ +5.62% | $2.19 (−27.24%) |
Jul 2, 2026 13w ago | 8-K | $2.63 $2.64 | ▲ +0.38% | ▼ −0.55% | $2.19 (−16.73%) |
Jun 30, 2026 13w ago | 144 | $2.85 $3.07 | ▲ +7.72% | ▲ +7.46% | $2.19 (−23.16%) |
Jun 30, 2026 13w ago | Press Release | $3.01 $2.46 | ▼ −18.27% | ▼ −18.88% | $2.19 (−27.24%) |
May 14, 2026 20w ago | 8-K | $2.21 $1.94 | ▼ −12.22% | ▼ −11.50% | $2.19 (−0.90%) |
May 14, 2026 20w ago | Press Release | $2.21 $1.94 | ▼ −12.22% | ▼ −11.50% | $2.19 (−0.90%) |
Apr 30, 2026 22w ago | DEFA14A | $1.70 $2.26 | ▲ +32.94% | ▲ +31.21% | $2.19 (+28.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access